# US 2008/0076101 A1 · Forming vascular diseases within anatomical models

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0076101 A1
- Document ID: US20080076101A1
- Status: Published application
- Kind: A1
- Application number: 11/748,374
- Filed: 2007-05-14
- Published: 2008-03-27
- Earliest claimed: 2006-05-12
- Assignees: Abbott Laboratories
- Inventors: Gregory Hyde; Jane Sifuentes; Kim Hayenga; Erik Eli; Jim Phelan; Ellen Roche
- Web page: https://patentgrep.com/patent/US20080076101A1

## CPC

- G09B 23/30: Anatomical models {(G09B23/281 - G09B23/288 take precedence)}
- G09B: EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS (devices for psychotechnics or for testing reaction times A61B5/16; games, sports, amusements A63; projectors, projector screens G03B)

## Abstract

Anatomical models are provided with simulated plaque, lesion, chronic total occlusion, as well as other vascular diseases that more accurately replicate these abnormalities. In such embodiment, the vascular disease may be formed separate from the structured anatomical model. The formed vascular disease material may then be bonded to or within a PVA material in a separate process from forming this simulated vascular disease, thus providing a replicated specific anatomy structure with an abnormality for demonstrating, testing, and/or developing medical functions and/or devices.

## Claims

### Claim 1

A method of creating poly(vinyl alcohol) (PVA) anatomical models with simulated abnormalities, the method comprising:
forming a simulated vascular disease from a first material for use in a structured model intended to replicate specific anatomies present in human or mammalian vessels, tissues, or both; and
bonding the first material to a PVA material in a separate process from forming the simulated vascular disease in order to replicate a specific anatomical structure with an abnormality.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anatomical structure with the abnormality is used for one or more of demonstrating, testing, or developing medial functions, devices, or both.

### Claim 3 (depends on 1)

The method of claim 1, wherein the bonding of the first material to the PVA material comprises:
creating a void in a portion of a core of a mold used for creating the specific anatomical structure, wherein the outer diameter of the core forms an offset from an outer diameter of the mold and is used to form the inner lining of the anatomical structure;
placing the first material in the void; and
filling the mold with the PVA material, wherein the PVA material is initially a liquid solution which is then at least partially cured to bond the simulated vascular disease within the specific anatomical structure.

### Claim 4 (depends on 3)

The method of claim 3, wherein the core material is a wax type material.

### Claim 5 (depends on 1)

The method of claim 1, wherein the bonding of the first material to the PVA material further comprises:
coating the first material of simulated vascular disease with a liquid PVA solution;
placing the PVA coated simulated vascular disease into the void of the core and sealing the mold around the core and the void;
injecting the PVA material into the mold, which fills the space created between the offset of the core and the outer diameter of the mold; and
at least partially curing the PVA material in order to produce a cross-linking between the PVA material and the PVA coated on the first material; thus ensuring that the simulated vascular disease does not flow downstream in the mold as the PVA material is injected into the mold.

### Claim 6 (depends on 1)

The method of claim 1, wherein the first material is a different material than the PVA.

### Claim 7 (depends on 1)

The method of claim 1, wherein the first material comprises one or more of a polyvinyl acetate-based glue, a PVA solution, sodium borate, a polymer, fiber, fabric, cyanoacrylate adhesive, or water.

### Claim 8 (depends on 1)

The method of claim 1, wherein the simulated vascular disease replicates one or more of a fatty plaque, chronic total occlusion, restenosis, fibrous plaque, friable plaque, or calcified lesion.

### Claim 9 (depends on 1)

The method of claim 1, wherein the bonding of the first material to the PVA material comprises:
coating the first material of simulated vascular disease with a liquid PVA solution;
placing the PVA coated simulated vascular disease onto the PVA material, which is partially cured and preformed into the specific anatomical structure; and
performing at least one curing cycle on the PVA coated first material and the PVA material of the specific anatomical structure in order to produce a cross-linking with the partially cured PVA thus ensuring that the simulated vascular disease material has a flexible, non-brittle connection with the specific anatomical structure.

### Claim 10

An anatomical model with one or more simulated plaque, lesion, chronic total occlusions, as well as other vascular diseases, which are formed separately in order to more accurately replicate such abnormalities within the anatomical model as opposed to just using a single vessel material in a onetime molding process, the anatomical model comprising:
a poly(vinyl alcohol) (PVA) material molded to replicate specific anatomies present in human or mammalian vessels, tissues, or both; and
a simulated vascular disease formed using a first material separate from the PVA material, which is then bonded therewith to replicate a specific anatomical structure with an abnormality for one or more of demonstrating, testing, or developing medial functions, devices, or both.

### Claim 11 (depends on 10)

The anatomical model of claim 10, wherein the bonding of the first material to the PVA material is done by applying liquid PVA to the formed simulated vascular disease and performing at least one cure cycle on the liquid PVA.

### Claim 12 (depends on 10)

The anatomical model of claim 10, wherein the first material is a PVA type material.

### Claim 13 (depends on 10)

The anatomical model of claim 10, wherein the first material comprises one or more of a polyvinyl acetate-based glue, a PVA solution, sodium borate, a polymer, fiber, fabric, cyanoacrylate adhesive, or water.

### Claim 14

A method of bonding simulated plaque, lesion, chronic total occlusions, or other vascular diseases in an anatomical model to more accurately replicate such abnormalities within the anatomical model as opposed to just using a single vessel material in a onetime molding process, the method comprising:
obtaining a simulated vascular disease made from one or more of a poly(vinyl alcohol) (PVA) solution, polyvinyl acetate-based glue, sodium borate, a polymer, fiber, fabric, cyanoacrylate adhesive, or water; and
bonding the simulated vascular disease to a PVA material in a separate process from forming the simulated vascular disease in order to replicate a specific anatomical structure with an abnormality present in human or mammalian vessels, tissues, or both.

### Claim 15 (depends on 14)

The method of claim 14, wherein the bonding of the simulated vascular disease to the PVA material comprises:
creating a void in a portion of a core of a mold used for creating the specific anatomical structure, wherein the core is an offset with an outer diameter of the mold and is used to form the inner lining of the anatomical structure;
placing the simulated vascular disease in the void; and
filling the mold with the PVA material, wherein the PVA material is initially a liquid solution which is then at least partially cured to bond the simulated vascular disease within the specific anatomical structure.

### Claim 16 (depends on 15)

The method of claim 15, wherein the bonding of the simulated vascular disease to the PVA material further comprises:
coating the simulated vascular disease with a liquid PVA solution;
placing the PVA coated simulated vascular disease into the void of the core and sealing the mold around the core and the void;
injecting the PVA material into the mold, which fills the space created between the offset of the core and the mold; and
at least partially curing the PVA material in order to produce a crosslink between the PVA material and the PVA coated simulated vascular disease in order to ensure that the simulated vascular disease does not flow downstream in the mold as the PVA material is injected into the mold.

### Claim 17 (depends on 14)

The method of claim 14, wherein the simulated vascular disease is not the same material as the PVA material.

### Claim 18 (depends on 14)

The method of claim 14, wherein the simulated vascular disease replicates one or more of a fatty plaque, chronic total occlusion, restenosis, fibrous plaque, friable plaque, or calcified lesion.

### Claim 19 (depends on 14)

The method of claim 14, wherein the bonding of the simulated vascular disease to the PVA material comprises:
coating the simulated vascular disease with a liquid PVA solution;
placing the PVA coated simulated vascular disease onto the PVA material, which is partially cured and preformed into the specific anatomical structure; and fully curing the PVA coated simulated vascular disease and the PVA material of the specific anatomical structure in order to produce a crosslink with the partially cured PVA thus ensuring that the simulated vascular disease material has a flexible, non-brittle connection with the specific anatomical structure.

### Claim 20 (depends on 19)

The method of claim 19, wherein the curing cycle is a freeze-thaw cycle performed manually or mechanically using one or more of an environmental, pressure, or both chamber, and a slurry of dry ice, alcohol, or both.
